The World's Best Long-Term Hope for Ending AIDS

The HVTN uses an integrated approach to HIV prevention to advance the fields of vaccinology, social and behavioral sciences, statistics, and immunology, as well as COVID-19 and tuberculosis (TB) vaccines.  

70+

Study Sites

Headquartered at Fred Hutch in Seattle, the Network includes over 70 sites on four continents staffed by teams with expertise in vaccinology, immunology, and in conducting clinical trials.

100+

Clinical Trials

For more than 20 years, the HVTN has conducted all phases of clinical trials based on the latest developments in vaccinology and immunology for the prevention of HIV, tuberculosis and COVID-19.

74

Scholar Awards

We are investing in the next generation of HIV prevention researchers with grants and mentoring for African American/Black and Hispanic/Latinx medical students.

HVTN Mission

Our mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally.

Who We Are

We are the world’s largest publicly-funded international collaboration focused on the evaluation of vaccines to prevent HIV/AIDS.

What We Do

Our sites conduct all phases of clinical trials — from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. 

Get Involved

Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development.

It Takes a Village

The HIV Vaccine Trials Network is an international partnership of research scientists, clinical trial sites, laboratories, statisticians, regulators and ethicists, participants, volunteers and community representatives working with industry, academia, and governments in the global search for a preventive HIV vaccine.

Recent HVTN News & Announcements

"Intersections" video series launches in October

"Intersections", a new video series of one-on-one interviews exploring the intersections of science and daily life. Hosted by Dr. Stephaun Wallace, External Relations Director of both the CoVPN and HVTN, conversations will feature prominent figures in science, business, politics, the arts, sports, fashion, activism, news media, and technology. 

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

A study published in the August 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1.

Community Compass latest issue

Read the Latest Community Compass Issue

In this edition we explore the intersection of faith and HIV with perspectives from HVTN Core staff and Faith Ambassadors, share information about the launch of a new marketing campaign aimed at supporting phase 1 enrollment, and share news of a new program aimed at increasing the scientific leadership of HVTN investigators.

News on HVTN

Read More
Test of a new 'germline-targeting' HIV vaccine prepares to launch Vaccine’s unique protein designed to start process of building powerful antibodies against AIDS virus May 19, 2022
HIV antibody trial results offer 'proof of concept' Outcome of AMP shows feasibility of developing potent antibody combinations to block HIV March 17, 2021
Community engagement in HIV trials guides equity for COVID-19 vaccine studies New study highlights longstanding barriers to diversity in prior decade of vaccine trials, despite federal guidelines February 19, 2021
Biostatisticians draft blueprints for COVID-19 vax trials Hutch group applies skills honed during decades of HIV prevention trials to bring about safe and effective vaccines for a new pandemic February 18, 2021

RAMP Scholar Grant

The Research and Mentorship Program (RAMP) provides structured mentorship and project funding to African American/Black and Hispanic/Latinx medical students in areas of basic, clinical behavioral, laboratory and social sciences.